Stevens Capital Closes Out Position in Eli Lilly

Stevens Capital Management LP fully divested its 12,036-share position in Eli Lilly (LLY) during Q2 2025, a holding previously representing 2.5% of the fund's AUM and valued at approximately $9.94 million. This exit, according to the article, may signal heightened competitive pressures within the lucrative weight-loss drug market, particularly as Novo Nordisk's oral Wegovy appears to be gaining an advantage over Eli Lilly's Zepbound in both efficacy (based on trial data) and anticipated regulatory approval timeline for oral formulations.

Analysis

Stevens Capital Management's complete divestment of its Eli Lilly (LLY) position in Q2 2025, liquidating 12,036 shares valued at approximately $9.94 million, signals a significant shift in institutional sentiment. This move, which eliminated a holding that was 2.5% of the fund's AUM, appears to be driven by escalating competitive risks in the weight-loss drug market. The primary threat stems from Novo Nordisk (NVO), whose oral version of Wegovy is not only ahead in the regulatory timeline, with an FDA decision expected in Q4 2025, but also demonstrated superior efficacy in Phase 3 trials with a 15.1% mean weight loss compared to the 12.4% for Lilly's oral candidate, orforglipron. This potential first-mover advantage and superior clinical data for NVO challenge Lilly's market dominance. The concern is amplified by LLY's recent stock underperformance, with a one-year total return of -23.1%, and a high forward P/E ratio of 32.15, which indicates that significant growth is still priced into the stock, making it vulnerable to negative catalysts.

Key Decisions for Investors

• Investors holding Eli Lilly should closely monitor the FDA's Q4 2025 decision on Novo Nordisk's oral Wegovy, as an approval could solidify a first-mover advantage and materially impact LLY's future revenue from its weight-loss franchise.
• The divergence in clinical trial efficacy between Novo Nordisk's and Eli Lilly's oral treatments warrants a re-evaluation of long-term market share assumptions for LLY in the highly competitive obesity market.
• Given the negative sentiment for LLY (-0.6) and positive sentiment for NVO (+0.7), a potential pairs trade or a reallocation of capital from LLY to NVO could be considered to position for the apparent shift in competitive leadership.
• Despite its recent price decline, Eli Lilly's forward P/E of 32.15 suggests valuation remains elevated, posing a risk of further de-rating if its oral drug pipeline fails to meet high market expectations or loses ground to competitors.